All In Biotech

Drug Trial Radar · NCT04975997

Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)

Last checked: Nov 20, 2026Latest source record: Apr 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 939 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

939

Actual

Start

Jun 23, 2022

Primary completion

Nov 16, 2027

Study completion Jun 25, 2032

Sponsor

Lead sponsor
CelgeneBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jul 26, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, two-stage, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).

Conditions

  • Multiple Myeloma

Interventions

  • DexamethasoneDrug

    Oral dexamethasone 40mg on days 1, 8, 15, 22 of a 28-day cycle

  • DaratumumabDrug

    Subcutaneous Daratumumab 1800mg on Days 1, 8, 15 and 22 for Cycles 1 to 2, on Days 1 and 15 for Cycles 3 to 6, and then on Day 1 for Cycle 7+ of a 28-day cycle

  • BortezomibDrug

    Subcutaneous Bortezomib 1.3 mg/m2 on Days 1, 4, 8 and 11 of each 21-day cycle for a total of 8 cycles.

  • IberdomideDrug

    Oral Iberdomide 1.0mg on Days 1 to 21 of a 28-day cycle

  • IberdomideDrug

    Oral Iberdomide 1.3mg on Days 1 to 21 of a 28-day cycle

  • IberdomideDrug

    Oral Iberdomide 1.6mg on Days 1 to 21 of a 28-day cycle

  • DexamethasoneDrug

    Oral dexamethasone 20mg on days 1,2, 4,5,8,9,11,12 of a 21-day cycle from cycles 1-8

  • DaratumumabDrug

    Subcutaneous daratumumab 1800mg Cycles 1 to 3 on Days 1, 8, 15 of a 21-day cycle, Cycles 4 to 8 on Day 1 of a 21-day cycle and Cycles 9+ on Day 1 of a 28-day cycle.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression-free Survival (PFS)Time frame: Up to approximately 5 years
  2. Minimal Residual Disease (MRD) negative Complete Response (CR) at any timeTime frame: Up to approximately 5 years

Locations

259 sites in 31 countries. Site status is shown where the registry gives one.

  • Local Institution - 035

    Hot Springs, Arkansas

  • Local Institution - 641

    Cerritos, California

  • Local Institution - 681

    Fountain Valley, California

  • Local Institution - 047

    Los Angeles, California

  • Local Institution - 684

    Newport, California

  • Local Institution - 033

    New Haven, Connecticut

  • Local Institution - 029

    Fort Myers, Florida

  • Local Institution - 693

    Ocala, Florida

  • Local Institution - 028

    St. Petersburg, Florida

  • Local Institution - 045

    Tamarac, Florida

  • Local Institution - 034

    West Palm Beach, Florida

  • Local Institution - 685

    Weston, Florida

  • Local Institution - 018

    Atlanta, Georgia

  • Local Institution - 640

    Elk Grove Village, Illinois

  • Local Institution - 697

    Dyer, Indiana

  • Local Institution - 040

    Louisville, Kentucky

  • Local Institution - 041

    Alexandria, Louisiana

  • Local Institution - 682

    Baton Rouge, Louisiana

  • Local Institution - 027

    Baton Rouge, Louisiana

  • Local Institution - 698

    Baltimore, Maryland

  • Local Institution - 014

    Bethesda, Maryland

  • Local Institution - 688

    Columbia, Maryland

  • Local Institution - 010

    Boston, Massachusetts

  • Local Institution - 009

    Worcester, Massachusetts

  • Local Institution - 645

    Burnsville, Minnesota

  • Local Institution - 031

    Kansas City, Missouri

  • Local Institution - 046

    Billings, Montana

  • Local Institution - 015

    Summit, New Jersey

  • Local Institution - 691

    New York, New York

  • Local Institution - 039

    Durham, North Carolina

  • Local Institution - 038

    Cincinnati, Ohio

  • Local Institution - 037

    Cleveland, Ohio

  • Local Institution - 008

    Cleveland, Ohio

  • Local Institution - 036

    Columbus, Ohio

  • Local Institution - 680

    Tulsa, Oklahoma

  • Local Institution - 043

    Portland, Oregon

  • Local Institution - 030

    Chattanooga, Tennessee

  • Local Institution - 021

    Nashville, Tennessee

  • Local Institution - 687

    Austin, Texas

  • Local Institution - 695

    Houston, Texas

Showing 40 of 259 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.